ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD – Get Rating) – Analysts at Zacks Research issued their Q2 2023 earnings per share (EPS) estimates for ACADIA Pharmaceuticals in a report released on Monday, May 22nd. Zacks Research analyst A. Chakroborty forecasts that the biopharmaceutical company will earn ($0.22) per share for the quarter. The consensus estimate for ACADIA Pharmaceuticals’ current full-year earnings is ($0.57) per share. Zacks Research also issued estimates for ACADIA Pharmaceuticals’ Q3 2023 earnings at ($0.10) EPS, Q4 2023 earnings at ($0.04) EPS, FY2023 earnings at ($0.63) EPS, Q1 2024 earnings at ($0.25) EPS, Q2 2024 earnings at ($0.12) EPS, Q3 2024 earnings at ($0.04) EPS, Q4 2024 earnings at ($0.09) EPS, FY2024 earnings at ($0.49) EPS, Q1 2025 earnings at ($0.13) EPS and FY2025 earnings at $0.27 EPS.
ACADIA Pharmaceuticals (NASDAQ:ACAD – Get Rating) last posted its earnings results on Monday, May 8th. The biopharmaceutical company reported ($0.27) earnings per share for the quarter, missing the consensus estimate of ($0.21) by ($0.06). The firm had revenue of $118.46 million during the quarter, compared to analyst estimates of $120.29 million. ACADIA Pharmaceuticals had a negative net margin of 28.05% and a negative return on equity of 35.70%. The firm’s revenue for the quarter was up 2.6% on a year-over-year basis. During the same period last year, the company posted ($0.70) EPS.
ACADIA Pharmaceuticals Stock Performance
ACADIA Pharmaceuticals stock opened at $25.65 on Thursday. The firm has a market capitalization of $4.17 billion, a price-to-earnings ratio of -28.19 and a beta of 0.54. ACADIA Pharmaceuticals has a fifty-two week low of $12.24 and a fifty-two week high of $25.73. The stock’s fifty day moving average is $20.37 and its two-hundred day moving average is $18.44.
Insider Transactions at ACADIA Pharmaceuticals
In other news, COO Brendan Teehan sold 1,751 shares of ACADIA Pharmaceuticals stock in a transaction that occurred on Thursday, April 6th. The stock was sold at an average price of $18.16, for a total value of $31,798.16. Following the completion of the transaction, the chief operating officer now owns 8,468 shares in the company, valued at approximately $153,778.88. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. In related news, COO Brendan Teehan sold 1,751 shares of the firm’s stock in a transaction that occurred on Thursday, April 6th. The stock was sold at an average price of $18.16, for a total value of $31,798.16. Following the sale, the chief operating officer now owns 8,468 shares of the company’s stock, valued at approximately $153,778.88. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Also, CEO Stephen Davis sold 3,851 shares of the firm’s stock in a transaction that occurred on Friday, February 24th. The stock was sold at an average price of $18.78, for a total value of $72,321.78. Following the completion of the sale, the chief executive officer now directly owns 91,727 shares in the company, valued at approximately $1,722,633.06. The disclosure for this sale can be found here. In the last quarter, insiders sold 66,368 shares of company stock worth $1,393,764. 28.40% of the stock is currently owned by corporate insiders.
Institutional Trading of ACADIA Pharmaceuticals
Several hedge funds have recently added to or reduced their stakes in the business. China Universal Asset Management Co. Ltd. raised its stake in ACADIA Pharmaceuticals by 33.6% during the 1st quarter. China Universal Asset Management Co. Ltd. now owns 2,198 shares of the biopharmaceutical company’s stock valued at $41,000 after acquiring an additional 553 shares in the last quarter. Amalgamated Bank raised its stake in shares of ACADIA Pharmaceuticals by 3.2% in the 4th quarter. Amalgamated Bank now owns 19,880 shares of the biopharmaceutical company’s stock worth $316,000 after buying an additional 622 shares in the last quarter. Handelsbanken Fonder AB raised its stake in shares of ACADIA Pharmaceuticals by 3.2% in the 4th quarter. Handelsbanken Fonder AB now owns 25,433 shares of the biopharmaceutical company’s stock worth $405,000 after buying an additional 800 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. raised its stake in shares of ACADIA Pharmaceuticals by 1.4% in the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 60,753 shares of the biopharmaceutical company’s stock worth $967,000 after buying an additional 844 shares in the last quarter. Finally, Commonwealth Equity Services LLC raised its stake in shares of ACADIA Pharmaceuticals by 6.6% in the 4th quarter. Commonwealth Equity Services LLC now owns 13,930 shares of the biopharmaceutical company’s stock worth $221,000 after buying an additional 865 shares in the last quarter. Institutional investors own 92.79% of the company’s stock.
ACADIA Pharmaceuticals Company Profile
ACADIA Pharmaceuticals, Inc is a biopharmaceutical company, which focuses on the development and commercialization of medicines to address unmet medical needs in central nervous system, or CNS, disorders. Its products include Nuplazid, which is used for the treatment of hallucinations and delusions associated with Parkinson’s disease psychosis.
Featured Stories
- Get a free copy of the StockNews.com research report on ACADIA Pharmaceuticals (ACAD)
- Toll Brothers Rises On Results, But The Roof Is In Place
- It’s Time To Try On VF Corporation’s 6% Yield
- PetCo Management Getting it Right? Earnings Beat Says Yes
- Axcelis Stock In Buy Range After Chart Breakout, Strong Guidance
- Kohl’s 10% Yield Comes Into High Fashion
Receive News & Ratings for ACADIA Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ACADIA Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
